Scientific Publications

A reading list of relevant scientific papers for the more interested researcher.

• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315-24.
• Avalos I, Chung CP, Oeser A, Gebretsadik T, Shintani A, Kurnik D, Raggi P, Sokka T, Pincus T, Stein CM. Increased augmentation index in rheumatoid arthritis and its relationship to coronary artery atherosclerosis. J Rheumatol. 2007 Dec;34(12):2388-94. Epub 2007 Nov 15.
• Barrett EM, Scott DG, Wiles NJ, Symmons DP. The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study. Rheumatology (Oxford). 2000 Dec;39(12):1403-9.
• Buckwalter JA, Saltzman C, Brown T. The impact of osteoarthritis: implications for research. Clin Orthop Relat Res. 2004 Oct;(427 Suppl):S6-15.
• Buttgereit F, Burmester G-R, Lipworth BJ. Optimized glucocorticoid therapy: the sharpening of an old spear. Lancet 2005;365:801-3.
• Buttgereit F, Doering G, Schaeffl er A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiff ness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008; 371: 205-14
• Buttgereit F, Saag KG, Cutolo M, da Silva JAP, Bijlsma JWJ. The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand J Rheumatol 2005;34:14-21.
• Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004;50:3408-17.
• Conn DL. Resolved: Low-dose prednisone is indicated as a standard treatment in patients with rheumatoid arthritis. Arthritis Rheum 2001;45:462-7.
• Crofford LJ, Kalogeras KT, Mastorakos G, Magiakou MA, Wells J, Kanik KS, et al. Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab 1997;82:1279-83.
• Cutolo M, Maestroni GJM, Otsa K, Aakre O, Villaggio B, Capellino S, et al. Circadian melatonin and cortisol levels in rheumatoid arthritis patients in winter time: a north and south Europe comparison. Ann Rheum Dis 2005;64:212-6.
• Cutolo M, Masi AT. Circadian rhythms and arthritis. Rheum Dis Clin N Am 2005;31:115-29.
• Cutolo M, Oliveri M, Secchi ME, Cimmino MA. Therapy of rheumatic polymyalgia: the pathophysiologic management. Reumatismo. 2007 Oct-Dec;59(4):271-9. Italian.
• Cutolo M, Seriolo B, Craviotto C, Pizzorni C, Sulli A. Circadian rhythms in RA. Ann Rheum Dis 2003;62:593 6.
• Cutolo M. Developments in Treatments for Rheumatoid Arthritis. European Musculoskeletal Review 2007; 22-24
• Da Silva JAP, Jacobs JWG, Kirwan JR, Boers M, Saag KG, Ines LBS, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheumatol Dis 2006;65:285-93.
• Green GA. Understanding NSAIDS: from aspirin to COX-2. Clin Cornerstone 2001; 3:50-60.
• Hickling P, Jacoby RK, Kirwan JR. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br J Rheumatol 1998;37:930-6.
• Hudson M, Baron M. Morning stiffness is a better predictor of function in early inflammatory arthritis than are swollen and tender joints. Arthritis Rheum 2005;52 Suppl 9: abstract 1036.
• Jacobs JWG, van Everdingen AA, Verstappen SMM, Bijlsma JWJ. Follow-up radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum 2006;54:1422-8.
• Jerussi TP, Caubet JF, McCray JE, Handley DA. Clinical endoscopic evaluation of the gastroduodenal tolerance to (R)- ketoprofen, (R)- flurbiprofen, racemic ketoprofen, and paracetamol: a randomized, single-blind, placebo-controlled trial. J Clin Pharmacol. 1998 Feb;38(2 Suppl):19S-24S.
• Kirwan JR, Boers M, Shea B. Glucocorticoids strongly suppress joint damage in rheumatoid arthritis: A meta-analysis of 1,414 patients in 15 trials. Arthritis Rheum 2005; 52 Suppl 9: abstract 891.
• Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995;333:142 6.
• Labbe P, Hardouin P. Epidemiology and optimal management of polymyalgia rheumatica. Drugs Aging. 1998 Aug;13(2):109-18.
• Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II. Arthritis Rheum. 2008 Jan;58(1):26-35.
• Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998 May;41(5):778-99.
• Lötsch J, Geisslinger G, Mohammadian P, Brune K, Kobal G. Effects of flurbiprofen enantiomers on pain-related chemo-somatosensory evoked potentials in human subjects. Br J Clin Pharmacol. 1995 Oct;40(4):339-46.
• Markenson JA. Worldwide trends in the socio-economic impact and long-term prognosis of rheumatoid arthritis. Sem Arthritis Rheum. 1991, 21: 4-12
• Martin RJ, Banks-Schlegel S. Chronobiology of asthma. Am J Respir Crit Care Med. 1998 Sep;158(3):1002-7.
• Myllykangas-Luosujärvi R, Aho K, Kautiainen H, Hakala M. Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland. Rheumatology (Oxford). 1999 Jun;38(6):499-503.
• Neeck G, Federlin K, Graef V, Rusch D, Schmidt KL. Adrenal secretion of cortisol in patients with rheumatoid arthritis. J Rheumatol 1990;17:24-9.
• Nishio Y, Isshiki H, Kishimoto T, Akira S. A nuclear factor for interleukin-6 expression (NF-IL6) and the glucocorticoid receptor synergistically activate transcription of the rat alpha 1-acid glycoprotein gene via direct protein-protein interaction. Mol Cell Biol. 1993 Mar;13(3):1854-62.
• Petrovsky N, McNair P, Harrison LC. Diurnal rhythms of pro-inflammatory cytokines: regulation by plasma cortisol and therapeutic implications. Cytokine 1998;10:307-12.
• Salvarani C, Gabriel SE, O’Fallon WM, Hunder GG. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991. Arthritis Rheum. 1995 Mar;38(3):369-73.
• Shigemitsu H, Afshar K. Nocturnal asthma. Curr Opin Pulm Med. 2007 Jan;13(1):49-55.
• Skloot GS. Nocturnal asthma: mechanisms and management. Mt Sinai J Med. 2002 May;69(3):140-7.
• Smith DH, Malone DC, Lawson KA, Okamoto LJ, Battista C, Saunders WB. A national estimate of the economic costs of
• Straub RH, Cutolo M. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum. 2007 Feb;56(2):399-408.
• Stucki G, Cieza A. The international classification of functioning, disability and health (ICF) core sets for rheumatoid arthritis: a way to specify functioning. Ann Rheum Dis
• Sulli A, Montecucco CM, Caporali R, Cavagna L, Montagna P, Capellino S, Fazzuoli L, Seriolo B, Alessandro C, Secchi ME, Cutolo M. Glucocorticoid effects on adrenal steroids and cytokine responsiveness in polymyalgia rheumatica and elderly onset rheumatoid arthritis. Ann N Y Acad Sci. 2006 Jun;1069:307-14.
• Sutherland ER. Nocturnal asthma. J Allergy Clin Immunol. 2005 Dec;116(6):1179-86; quiz 1187. Epub 2005 Nov 8.
• Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafström J. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005;52:3360-70.
• van Everdingen AA, Jacobs JWG, Siewertsz van Reesema DR, Bijlsma JWJ. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects. A randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002;136:1-12.
• van Everdingen AA, Jacobs JWG, Siewertsz van Reesema DR, Bijlsma JWJ. Low-dose glucocorticoids in early rheumatoid arthritis: Discordant effects on bone mineral density and fractures? Clin Exper Rheumatol 2003;21:155-60.
• Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years. Arthritis Rheum 2005;52:3371-80.
• Yokoyama A, Kohno N, Fujino S, Hamada H, Inoue Y, Fujioka S, Ishida S, Hiwada K. Circulating interleukin-6 levels in patients with bronchial asthma. Am J Respir Crit Care Med. 1995 May;151(5):1354-8.